IDiyas

For the Inventor, By the Inventor

San Carlos, CA, United States of America

Miroslav Rapta

USPTO Granted Patents = 62 

 

 

Average Co-Inventor Count = 3.0

ph-index = 12

Forward Citations = 347(Granted Patents)

Forward Citations (Not Self Cited) = 234(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Sunnyvale, CA (US) (2008 - 2014)
  • San Carlos, CA (US) (2012 - 2023)

Company Filing History:

goldMedal40 out of 262 
 
Theravance Biopharma R&d Ip, LLC
 patents
silverMedal22 out of 386 
 
Theravance, Inc.
 patents

Years Active: 2008-2025

Loading Chart...
Loading Chart...
Loading Chart...
62 patents (USPTO):
1. 12351561 - Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2025-07-08),
2. 12239638 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound (2025-03-04),
3. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease (2023-08-08),
4. 11718591 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof (2023-08-08),
5. 11642332 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2023-05-09),
6. 11596624 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound (2023-03-07),
7. 11230536 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2022-01-25),
8. 11033533 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2021-06-15),
9. 10968205 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors (2021-04-06),
10. 10946006 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound (2021-03-16),
11. 10752599 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2020-08-25),
12. 10640467 - Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid (2020-05-05),
13. 10576073 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound (2020-03-03),
14. 10548879 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2020-02-04),
15. 10538513 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors (2020-01-21),

Title: Miroslav Rapta: Innovator in Respiratory Disease Treatments

Introduction

Miroslav Rapta is a prominent inventor based in San Carlos, California, known for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio of 60 patents, Rapta has dedicated his career to developing novel compounds and treatments aimed at addressing critical health challenges, particularly in respiratory diseases.

Latest Patents

Among Rapta's recent innovations is a patent for JAK kinase inhibitor compounds that focus on the treatment of respiratory diseases. This invention details compounds of a specific formula, including a method for their application in treating such conditions. Additionally, he has patented a crystalline form of a compound known for its neprilysin inhibition activity, which is also used in pharmaceutical compositions. This innovation relates to processes for preparing both soluble and crystalline forms of the compound, showcasing his commitment to advancing therapeutic strategies.

Career Highlights

Miroslav Rapta's career includes significant roles at Theravance Biopharma R&D IP, LLC and Theravance, Inc. His work at these companies has been instrumental in the progression of pharmaceutical research, particularly in developing compounds that can effectively combat respiratory diseases. His extensive patent portfolio reflects a deep understanding of both chemical compounds and their clinical applications.

Collaborations

Throughout his career, Rapta has collaborated with esteemed colleagues, including Venkat R Thalladi and Pierre-Jean Colson. These collaborations have further enriched his research and contributed to the development of innovative therapeutic solutions.

Conclusion

Miroslav Rapta's work exemplifies the vital intersection of innovation and healthcare. With numerous patents to his name and a focus on respiratory disease treatment, his contributions are invaluable in the ongoing pursuit of effective medical therapies. As researchers and industries continue to benefit from his innovations, Rapta's legacy as a leading inventor in the pharmaceutical field is well established.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…